USA San Francisco and China Suzhou, November 25, 2024 / PRNewswire / -- Innovent Bio, a biopharmaceutical group (Hong Kong Stock Exchange code: 01801) dedicated to researching, producing, and selling innovative drugs in the areas of oncology, autoimmunity, metabolism, cardiovascular, ophthalmology, and other major diseases, announced today that it will present nearly 10 clinical data at the 2024 European Society for Medical Oncology Asia Conference (ESMO Asia), including 2 oral presentations, including the phase I update data of IBI343 (innovative TOPO1i CLDN18.2 ADC) for the treatment of pancreatic cancer. The ESMO Asia Conference will be held in Singapore from December 6 to 8, 2024 local time.
Detailed summary information is as follows:
Oral presentation
Summary Title: IBI343, an anti-Claudin18.2 (CLDN18.2) ADC drug, in the treatment of advanced pancreatic ductal adenocarcinoma (PDAC): Phase I study data update
Abstract Number: 132MO
Presentation format: Mini Oral
Presentation time: December 7, 2024, 09:50-09:55
Speaker: Professor Zhang Jian, Fudan University Affiliated Tumor Hospital
Abstract Title: mFOLFOX6 + bevacizumab + sintilimab (PD-1 antibody) therapy for locally advanced MSS-type colorectal cancer: A prospective, single-arm, open-label phase II study (BASKET II)
Abstract number: 74MO
Presentation format: Mini Oral
Presentation time: December 7, 2024, 10:20-10:25
Speaker: Professor Huang Jun, The Sixth Affiliated Hospital of Sun Yat-sen University.
Wall poster display
Abstract Title: Xindili monoclonal antibody combined with anlotinib in first-line treatment of advanced colorectal cancer (APICAL-CRC): An open-label, single-arm, Phase II study.
Abstract Number: 75P
Display format: poster
Presentation Time: December 7, 2024, 17:50-18:45
Speaker: Professor Wang Zhan, Changhai Hospital, Shanghai
Abstract Title: A single-arm, multicenter, Phase II study (CHANCE 2203) of hepatic arterial infusion chemotherapy (HAIC) combined with sintilimab and donafenib as first-line treatment for unresectable intrahepatic cholangiocarcinoma
Abstract Number: 137P
Display format: poster
Presentation Time: December 7, 2024, 17:50-18:45
Speaker: Professor Teng Gaojun, Zhongda Hospital affiliated to Southeast University
Summary Title: FOLFOX-HAIC Combined with Sintilimab and Bevacizumab in the Treatment of Advanced Liver Cancer: A Single-Arm Phase II Study
Abstract Number: 207P
Display format: poster
Presentation Time: December 7, 2024, 17:50-18:45
Speaker: Professor Liang Bin/Wang Zizhuo, Tongji Medical College, Huazhong University of Science and Technology Affiliated Hiap Hoe Hospital
Summary Title: Update on Phase II Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined with Sintilimab and Bevacizumab for the Treatment of Advanced Liver Cancer Patients
Abstract Number: 214P
Display format: poster
Exhibition time: December 7, 2024, 17:50-18:45
Speaker: Professor Zhang Haibin, Shanghai Eastern Hepatobiliary Surgery Hospital
Chinese Title: Sindilimab Combined with Anlotinib vs. Immunotherapy Combined with Chemotherapy for Neoadjuvant NSCLC: Phase II Clinical Study
Abstract number: 599P
Display format: poster
Exhibition time: December 7, 2024, 17:50-18:45
Speaker: Professor Chu Tianqing, Shanghai Jiaotong University Affiliated Thoracic Hospital
Proposal Presentation (TiP)
Abstract Title: A randomized, controlled, multicenter phase 3 study of IBI310 (anti-CTLA-4 antibody) in combination with sintilimab as neoadjuvant treatment for resectable MSI-H/dMMR colon cancer: ongoing
Abstract Number: 119TiP
Display format: poster
Presentation Time: December 7, 2024, 17:50-18:45
Speaker: Professor Xu Ruihua, Cancer Prevention and Treatment Center, Sun Yat-sen University
Abstract Title: Efficacy and safety of sintilimab combined with chemotherapy and cryoablation as first-line treatment for advanced non-squamous non-small cell lung cancer
Abstract Number: 722TiP
Display format: poster
Presentation Time: December 7, 2024, 17:50-18:45
Speaker: Professor Gao Zhiqiang, Department of Thoracic Surgery, affiliated with Shanghai Jiaotong University
Dr. Zhou Hui, Senior Vice President of Innovent Bio, said:"I am delighted to continue updating our multiple groundbreaking clinical data at this ESMO Asia conference, especially in the globally challenging pancreatic cancer. Innovent Bio's innovative TOPO1i CLDN18.2 ADC IBI343, based on the preliminary efficacy signals in the early small group of people, after expanding the cohort, still observed encouraging efficacy signals and good safety. IBI343, with its unique antibody-end Fc silencing design, stable linker, and potent extecan payload, has become the most advanced CLDN18.2 ADC molecule in PDAC treatment. As one of the few biopharmaceutical companies with an "IO+ADC" technology platform and abundant pipeline reserves, Innovent Bio will continue to make breakthroughs in cancer treatment, dedicated to providing more innovative, effective, and safe treatment methods and solutions for doctors and patients."
"Starting with trust and ending with action", developing high-quality biopharmaceuticals that the general public can afford is the ideal and goal of Innovent Biologics. Innovent Biologics was established in 2011 and is committed to the development, production, and sales of innovative drugs to treat major diseases such as tumors, metabolic diseases, and autoimmune diseases. On October 31, 2018, Innovent Biologics went public on the Main Board of the Hong Kong Stock Exchange with stock code: 01801. Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model. It has established a product chain including 23 new drug varieties, covering multiple disease areas such as tumors, metabolic diseases, and autoimmune diseases, of which 6 varieties have been selected for the national "Major New Drug Creation" special project, and 3 products (Sintilimab Injection, brand name: Tyvyt, English trademark: TYVYT; Bevacizumab Injection, brand name: Duligotong, English trademark: BYVASDA; Camrelizumab Injection, brand name: Sulinno, English trademark: SULINNO) have been approved.
"Starting from trust and ending in action", developing high-quality biopharmaceuticals that ordinary people can afford is the mission and goal of LBX Pharmacy Chain Joint Stock. Established in 2011, LBX Pharmacy Chain Joint Stock is committed to researching, producing, and selling innovative drugs in the fields of oncology, autoimmunity, metabolism, ophthalmology, and other major diseases, benefiting more lives through our work. The company has already had 11 products approved for listing, namely Xindi Librow Injection (Dabosu), Bevacizumab Injection (Duyoutong), Adalimumab Injection (Sulixin), Rituximab Injection (Dabohua), Pemetrexed Tablets (Dabotan), Osimertinib Tablets (Nailike), Ramucirumab Injection (Xiziranzhe), Sunitinib Capsules (Ruituo), Efgartigimod Injection (Fukesu), Toripalimab Injection (Xinbile), and Fruquenecin tablets (Dabote). Currently, there are also 5 varieties under review by the National Medical Products Administration (NMPA), 3 new drug molecules entering Phase III or pivotal clinical studies, and another 17 new drug varieties in clinical research.
The company has reached more than 30 strategic cooperation agreements with international partners such as Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center. While seeking self-development through independent research and development of innovative drugs, Innovent adheres to the development concept of economic construction centering on the people. Over the years, it has always had a scientific and kind heart, stuck to the principle of "patient-centered," concerned about the patients and their families, and actively fulfilled its social responsibilities. The company has launched and participated in a number of drug public welfare assistance projects, enabling more and more patients to benefit from the progress of life sciences and buy and afford high-quality biological drugs. Up to now, Innovent's patient assistance project has benefited more than 170,000 ordinary patients, and the total value of drug donations is 3.4 billion yuan. Innovent hopes to work together with everyone to improve the development level of China's biopharmaceutical industry, to meet the accessibility of the people's medication and the pursuit of a better life and health.
For more details, please visit the company's website: [insert website link] or the company's LinkedIn account.
Statement: 1. Innovent Bio does not recommend the use of unapproved drugs/indications.
Leimoceumab injection (Xiranze) and Sipuleucel-T capsules (Ruite) were developed by Eli Lilly and Co.
Forward-looking statements
This press release may contain certain forward-looking statements. These statements inherently involve risks and uncertainties. When using words such as "expect," "believe," "anticipate," "intend," "plan," and other similar expressions, it is the company's intention to identify forward-looking statements. The company has no obligation to continually update these forward-looking statements.
These forward-looking statements are based on management's current views, assumptions, expectations, estimates, forecasts, and understandings of future events, which are inherently subject to risks, uncertainties, and other factors, some of which are beyond the company's control, and may be difficult to predict. Therefore, actual results may differ materially from those included in the forward-looking statements due to future changes and developments in our business, competitive environment, politics, economy, laws, and social circumstances.
